TY - JOUR
T1 - Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes
AU - Sánchez-Castro, Judit
AU - Marco-Betés, Víctor
AU - Gómez-Arbonés, Xavier
AU - Garciá-Cerecedo, Tomás
AU - López, Ricard
AU - Talavera, Elisabeth
AU - Fernández-Ruiz, Sara
AU - Ademà, Vera
AU - Marugan, Isabel
AU - Lunõ, Elisa
AU - Sanzo, Carmen
AU - Vallespí, Teresa
AU - Arenillas, Leonor
AU - Marco Buades, Josefa
AU - Batlle, Ana
AU - Bunõ, Ismael
AU - Martín Ramos, Mariá Luisa
AU - Blázquez Rios, Beatriz
AU - Collado Nieto, Rosa
AU - Vargas, Ma Teresa
AU - González Martínez, Teresa
AU - Sanz, Guillermo
AU - Solé, Francesc
N1 - Funding Information:
This work was supported in part by a grant from the Instituto de Salud Carlos III, Ministerio de Economía y Competi-tividad, Spain (PI 11/02010 and PI/14/00013); by the Red Temática de Investigación Cooperativaen Cáncer (RTICC, FEDER) (RD12/0036/0044); Sociedad Española Hematología y Hemoterapia; 2014 SGR225 (GRE) Generalitat de Cata-lunya, by José Carreras Leukämie-Stiftung, Ref. AR 14/34; financial support from Fundació Internacional Josep Car-reras and from Celgene Spain. The research leading to this invention has received funding from “la Caixa” Foundation.
Funding Information:
Medical writing support was provided by Sandra Lee Lewis of the Investigator-Initiated Research Writing Group (part of the KnowledgePoint360 Group), and was funded by Celgene.
Publisher Copyright:
© 2015 Informa UK, Ltd.
PY - 2015/11/2
Y1 - 2015/11/2
N2 - Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematological Cytogenetics. FISH detected-17 or 17p abnormalities in 13 cases (2.6%) in whom no 17p abnormalities were revealed by CC: 0.9% of patients with a normal karyotype, 0% in non-informative cytogenetics, 50% of patients with a chr17 abnormality without loss of 17p and 4.7% of cases with an abnormal karyotype not involving chr17. Our results suggest that applying FISH of 17p13 to identify the number of copies of the TP53 gene could be beneficial in patients with a complex karyotype.
AB - Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematological Cytogenetics. FISH detected-17 or 17p abnormalities in 13 cases (2.6%) in whom no 17p abnormalities were revealed by CC: 0.9% of patients with a normal karyotype, 0% in non-informative cytogenetics, 50% of patients with a chr17 abnormality without loss of 17p and 4.7% of cases with an abnormal karyotype not involving chr17. Our results suggest that applying FISH of 17p13 to identify the number of copies of the TP53 gene could be beneficial in patients with a complex karyotype.
KW - chromosome 17
KW - cytogenetics
KW - FISH
KW - Myelodysplastic syndromes
UR - http://www.scopus.com/inward/record.url?scp=84947767384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947767384&partnerID=8YFLogxK
U2 - 10.3109/10428194.2015.1028053
DO - 10.3109/10428194.2015.1028053
M3 - Article
C2 - 25754580
AN - SCOPUS:84947767384
SN - 1042-8194
VL - 56
SP - 3183
EP - 3188
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -